1. Home
  2. FRBA vs CMPX Comparison

FRBA vs CMPX Comparison

Compare FRBA & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FRBA

First Bank

HOLD

Current Price

$19.02

Market Cap

414.6M

Sector

Finance

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$2.25

Market Cap

408.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRBA
CMPX
Founded
2007
2014
Country
United States
United States
Employees
336
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
414.6M
408.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
FRBA
CMPX
Price
$19.02
$2.25
Analyst Decision
Buy
Strong Buy
Analyst Count
2
9
Target Price
$17.50
$14.57
AVG Volume (30 Days)
94.5K
3.2M
Earning Date
04-27-2026
05-06-2026
Dividend Yield
2.40%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.68
N/A
Revenue Next Year
$6.08
$934.41
P/E Ratio
$9.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.41
$1.61
52 Week High
$19.18
$6.88

Technical Indicators

Market Signals
Indicator
FRBA
CMPX
Relative Strength Index (RSI) 63.34 57.56
Support Level $16.84 $1.88
Resistance Level $19.09 $2.47
Average True Range (ATR) 0.42 0.12
MACD -0.01 0.04
Stochastic Oscillator 81.48 74.77

Price Performance

Historical Comparison
FRBA
CMPX

About FRBA First Bank

First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of business. Its services are Business Banking, Personal Banking, Digital Banking, and Lending.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: